Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Inclusion Criteria: * Must have Genotype 1a, 1b, 4 or 6 HCV infection. * Documented clinical history compatible with chronic hepatitis C * HCV treatment-naïve or interferon/RBV-treatment relapsed (Part C) * Must agree to use an acceptable double method of birth control (one of which must be a barrier method) for at least 6 months after the last dose of study drugs. Exclusion Criteria: * Female participants who are pregnant or breastfeeding. * Body Mass Index (BMI) \> 36 kg/m2. * Co-infected with hepatitis B virus or human immunodeficiency virus (HIV). * History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC. * History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency. * Has one or more known primary or secondary causes of liver disease, other than hepatitis C * History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, non-HCV viral hepatitis, gallstones or other etiologies * Donated blood or had significant blood loss 30 days prior to dosing